Experienced in Porphyria

Dr. Jay C. Andersen

Northwest Cancer Specialists PC
Portland, OR
Experienced
in Porphyria
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Jay Andersen is a Hematologist Oncology specialist and a Hematologist in Portland, Oregon. Dr. Andersen and is rated as an Experienced provider by MediFind in the treatment of Porphyria. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Porphyria. Dr. Andersen is currently accepting new patients.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in OR
Hospital Affiliations
Providence Newberg Medical Center
Legacy Meridian Park Medical Center
Providence Milwaukie Hospital
Providence St Vincent Medical Center
Legacy Good Samaritan Medical Center
Languages Spoken
English
Portuguese
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  BridgeSpan
  •  PacificSource
  •  Moda Health
  •  Premera
  •  Regence
  •  Prominence Health
View 1 More Insurance +

Locations

NORTHWEST CANCER SPECIALISTS PC
265 N Broadway, Portland, OR 97227
503-280-1223
Other Locations
NORTHWEST CANCER SPECIALISTS PC
5050 Ne Hoyt St, Suite 256, Portland, OR 97213
503-239-7767
NORTHWEST CANCER SPECIALISTS PC
210 Se 136th Ave, Vancouver, WA 98684
360-944-9889
NORTHWEST CANCER SPECIALISTS PC
12123 Sw 69th Ave, Tigard, OR 97223
971-708-7600

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drugs: tucatinib, trastuzumab deruxtecan
Study Phase: Phase 2
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
Enrollment Status: Terminated
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Sacituzumab Govitecan-hziy
Study Phase: Phase 2
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 14, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

8 Total Publications

Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
Journal: Breast cancer (Tokyo, Japan)
Published: March 14, 2024
Similar Doctors
Thomas G. Deloughery
Expertise in
56
conditions
Dr. Thomas G. Deloughery
Hematology | Hematology Oncology | Oncology
Expertise in
56
conditions
Dr. Thomas G. Deloughery
Hematology | Hematology Oncology | Oncology

University Professional Services

3303 S Bond Ave, 
Portland, OR 
 (2.5 mi)
503-494-8311
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Deloughery is a Hematologist and a Hematologist Oncology provider in Portland, Oregon. Dr. Deloughery and is rated as a Distinguished provider by MediFind in the treatment of Porphyria. His top areas of expertise are Iron Deficiency Anemia, Venous Thromboembolism (VTE), Paroxysmal Nocturnal Hemoglobinuria (PNH), Splenectomy, and Hormone Replacement Therapy (HRT). Dr. Deloughery is currently accepting new patients.

Expertise in
4
conditions
Dr. Lucy R. Langer
Hematology Oncology | Hematology | Oncology
Expertise in
4
conditions
Dr. Lucy R. Langer
Hematology Oncology | Hematology | Oncology

Northwest Cancer Specialists PC

5050 Ne Hoyt St, Suite 256, 
Portland, OR 
 (2.9 mi)
503-239-7767
Languages Spoken:
English, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Lucy Langer is a Hematologist Oncology specialist and a Hematologist in Portland, Oregon. Dr. Langer and is rated as an Advanced provider by MediFind in the treatment of Porphyria. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Virilizing Ovarian Tumor, and Ovarian Carcinosarcoma. Dr. Langer is currently accepting new patients.

Expertise in
19
conditions
Dr. John E. Godwin
Hematology | Hematology Oncology
Expertise in
19
conditions
Dr. John E. Godwin
Hematology | Hematology Oncology
4805 Ne Glisan St Ste 6n40, 
Portland, OR 
 (3.4 mi)
503-215-5696
Languages Spoken:
English
See accepted insurances

John Godwin is a Hematologist and a Hematologist Oncology provider in Portland, Oregon. Dr. Godwin and is rated as an Advanced provider by MediFind in the treatment of Porphyria. His top areas of expertise are Acute Myeloid Leukemia (AML), Multiple Myeloma, Melanoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile